JW BioScience licenses out pancreatic cancer biomarker technology to Immunovia
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
The license agreement encompasses key diagnostic technology developed to detect early-stage pancreatic cancer based on the use of two biomarkers of CFB and CA19-9. JW BioScience is a marketing right holder of the technology in Korea, the U.S., 21 European countries, China, and Japan.
The deal gives Immunovia global commercial rights for the technology, but the details and deal size are not disclosed as agreed by both parties.
The contract represents a recognition of the excellence of JW technology in the global market and JW will be able to further strengthen its technological competitiveness through the collaboration with Immunovia, said JW Bioscience CEO Hahm Eun-kyung.
JW BioScience is developing an early diagnosis kit that uses these biomarkers to detect pancreatic cancer.
Immunovia AB develops and sells highly accurate blood tests for the early detection of cancer and autoimmune disorders based on its own platform.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Shinhan Asset to merge with Shinhan Alternative for synergy, diversification - Pulse by Maeil Business News Korea
- HLB Group to put Covid-19 vaccine distributor G-TreeBNT under its arms - Pulse by Maeil Business News Korea
- Hyundai Motor chief expects robots to create new human jobs while replacing old jobs - Pulse by Maeil Business News Korea
- GC LabCell merges with GC Cell for synergy in cell therapy market - Pulse by Maeil Business News Korea
- WKF musters wisdom to respond to global challenges of inequality, climate change - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- [SPECIAL REPORT 1] 뜨거운 미국 주식시장 이제라도 올라타볼까
- ‘음주 운전’ 김새론, 연극 ‘동치미’ 하차...연기 복귀 노렸지만 ‘부정적 여론’에 무산 - MK
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이